TNF-related Apoptosis-inducing Ligand (TRAIL) in Rheumatoid Arthritis: What's New?

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2013 Jan 1

PMID 23275079

Citations 7

Authors

Anna Neve

Addolorata Corrado

Francesco Paolo Cantatore

Affiliations

Soon will be listed here.

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein of the TNF superfamily that serves as an extracellular signal that triggers programmed cell death in tumor cells, without affecting normal cells. Recently, scientists have turned their attention to the emerging role of TRAIL in immune and autoimmune responses. TRAIL has been shown to down-regulate the self-antigens in autoimmune diseases, such as rheumatoid arthritis (RA) by exerting its apoptotic effect on activated T cells and synoviocytes and by its local anti-inflammatory effect. The impact of TRAIL molecular variants and agonistic monoclonal antibodies in the regulation of TRAIL activity in arthritis animal models strongly supports the idea of testing the role of TRAIL in humans, with the aim of developing new effective therapies that promote apoptosis of synoviocytes and/or infiltrating lymphocytes, by targeting TRAIL. The aim of this review is to summarize recent progress and current knowledge of TRAIL functions in RA.

Citing Articles

Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children.

Jia X, Toda K, He L, Miao D, Yamada S, Yu L J Clin Endocrinol Metab. 2022; 107(7):1825-1832.

PMID: 35460250 PMC: 9391606. DOI: 10.1210/clinem/dgac256.

Mechanism of Action of Acupotomy in Inhibiting Chondrocyte Apoptosis in Rabbits with KOA through the PI3K/Akt Signaling Pathway.

Huang X, Geng K, Luo S, Liu C, Yang K, Zhai A Evid Based Complement Alternat Med. 2020; 2020:4241917.

PMID: 33224251 PMC: 7673938. DOI: 10.1155/2020/4241917.

Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis.

Malemud C Cells. 2018; 7(12).

PMID: 30469466 PMC: 6316166. DOI: 10.3390/cells7120223.

Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.

Shlyakhtina Y, Pavet V, Gronemeyer H Cell Death Dis. 2017; 8(8):e3025.

PMID: 29048428 PMC: 5596601. DOI: 10.1038/cddis.2017.423.

Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Croft M, Siegel R Nat Rev Rheumatol. 2017; 13(4):217-233.

PMID: 28275260 PMC: 5486401. DOI: 10.1038/nrrheum.2017.22.

References

Schneider P, Bodmer J, Thome M, Hofmann K, Holler N, Tschopp J . Characterization of two receptors for TRAIL. FEBS Lett. 1997; 416(3):329-34. DOI: 10.1016/s0014-5793(97)01231-3. View

Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . APO2 ligand: a novel lethal weapon against malignant glioma?. FEBS Lett. 1998; 427(1):124-8. DOI: 10.1016/s0014-5793(98)00409-8. View

Pundt N, Peters M, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K . Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther. 2009; 11(1):R16. PMC: 2688248. DOI: 10.1186/ar2607. View

Andersson I, Batsalova T, Dzhambazov B, Edvinsson L, Holmdahl R, Kihlberg J . Oxazole-modified glycopeptides that target arthritis-associated class II MHC A(q) and DR4 proteins. Org Biomol Chem. 2010; 8(13):2931-40. DOI: 10.1039/c003640d. View

SNELL V, Clodi K, Zhao S, Goodwin R, Thomas E, Morris S . Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997; 99(3):618-24. DOI: 10.1046/j.1365-2141.1997.4393250.x. View

Na S, Chae S, Lee S, Park K, Kim K, Park J . Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. Int J Pharm. 2008; 363(1-2):149-54. DOI: 10.1016/j.ijpharm.2008.07.013. View

Kim Y, Chae S, Jin C, Sivasubramanian M, Son S, Choi K . Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. Biomaterials. 2010; 31(34):9057-64. DOI: 10.1016/j.biomaterials.2010.08.015. View

Schneemann M, Schoeden G . Macrophage biology and immunology: man is not a mouse. J Leukoc Biol. 2007; 81(3):579. DOI: 10.1189/jlb.1106702. View

Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T . TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2003; 171(2):1061-9. DOI: 10.4049/jimmunol.171.2.1061. View

10.

Halaas O, Vik R, Ashkenazi A, Espevik T . Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol. 2000; 51(3):244-50. DOI: 10.1046/j.1365-3083.2000.00671.x. View

11.

Emery J, McDonnell P, Burke M, Deen K, Lyn S, SILVERMAN C . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273(23):14363-7. DOI: 10.1074/jbc.273.23.14363. View

12.

Terzioglu E, Bisgin A, Sanlioglu A, Ulker M, Yazisiz V, Tuzuner S . Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford). 2007; 46(5):783-9. DOI: 10.1093/rheumatology/kel448. View

13.

Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F . Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun. 2003; 312(2):397-404. DOI: 10.1016/j.bbrc.2003.10.141. View

14.

Allen J, El-Deiry W . Regulation of the human TRAIL gene. Cancer Biol Ther. 2012; 13(12):1143-51. PMC: 3469471. DOI: 10.4161/cbt.21354. View

15.

Maddipatla S, Hernandez-Ilizaliturri F, Knight J, Czuczman M . Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res. 2007; 13(15 Pt 1):4556-64. DOI: 10.1158/1078-0432.CCR-07-0680. View

16.

Xie Y, Jin L, Yu Q . [The role of IFN-gamma, IL-10, IL-12 and TRAIL in sera and synovium fluids from patients with rheumatoid arthritis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007; 23(6):536-7. View

17.

Liu Z, Xu X, Hsu H, Tousson A, Yang P, Wu Q . CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest. 2003; 112(9):1332-41. PMC: 228459. DOI: 10.1172/JCI19209. View

18.

Martinez-Lostao L, Garcia-Alvarez F, Basanez G, Alegre-Aguaron E, Desportes P, Larrad L . Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum. 2010; 62(8):2272-82. DOI: 10.1002/art.27501. View

19.

Morales-Lara M, Canete J, Torres-Moreno D, Hernandez M, Pedrero F, Celis R . Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine. 2012; 79(6):591-6. DOI: 10.1016/j.jbspin.2012.02.003. View

20.

Mariani S, Krammer P . Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 1998; 28(3):973-82. DOI: 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T. View